Propanc Biopharma, Inc. (PPCB) Reports Preclinical Data Suggesting PRP May Re-Sensitize Chemo-Resistant Cells

Propanc Biopharma (NASDAQ:PPCB) published a peer-reviewed study in Scientific Reports on its pancreatic proenzyme combination PRP, showing anti-tumor efficacy in lab and animal models, and improved survival in human patients. The study evaluated PRP's impact on 24 cancer cell lines, with significant tumor weight reduction and no adverse events reported. The company is developing PRP for pancreatic, ovarian, and refractory prostate cancers.

Propanc Biopharma (PPCB) reported preclinical data for PRP, showing over 90% tumor growth inhibition and extended survival in pancreatic cancer models. PRP, with FDA Orphan Drug Designation, targets cancer biology aspects beyond RAS mutations. The company plans a Phase 1b trial in Q1 2027. PPCB stock closed at $0.49, up 1.51%.

Propanc Biopharma (PPCB) reported preclinical data for its PRP treatment in advanced pancreatic cancer, which has FDA Orphan Drug Designation. The company plans to begin a Phase 1b clinical trial in Q1 2027. PRP is still in early-stage development, and further regulatory approvals are required.

Propanc Biopharma (Nasdaq: PPCB) reported preclinical data showing its lead candidate PRP achieved over 90% tumor growth inhibition in pancreatic cancer models. PRP targets different mechanisms than Revolution Medicines' recently approved daraxonrasib, which showed median overall survival of 13.2 months in clinical trials. Propanc plans to start a Phase 1b study in early 2027.

Propanc Biopharma (PPCB) reported preclinical data showing its lead candidate PRP achieved over 90% tumor growth inhibition in pancreatic cancer models. PRP also reduced metastasis, improved chemotherapy sensitivity, and extended survival. The company completed a 1-for-25 reverse stock split and shares surged 202.75% to $3.22.

Propanc Biopharma (PPCB) reported positive preclinical data for PRP in pancreatic cancer, showing over 90% tumor growth inhibition and extended survival in models. The treatment also improved chemo-resistance and tumor environment. PPCB stock surged 249.59% to $3.69 on Nasdaq. The company plans a Phase 1b study with a clinical trial application expected soon.